Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction

Journal of Physiology

Volumn 580, Issue 3, 2007, Pages 907-923

  Merkus, Daphne ^a   Houweling, Birgit ^a   de Beer, Vincent J ^a   Everon, Zaida ^a   Duncker, Dirk J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; INDOMETACIN; N(G) NITROARGININE; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE; PROSTANOID; TEZOSENTAN; PROSTAGLANDIN; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL TONE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; SWINE; TREADMILL EXERCISE; VASODILATATION; ADRENERGIC SYSTEM; ANIMAL; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; AEROBIC METABOLISM; AORTA PRESSURE; BLOOD GAS ANALYSIS; BLOOD SAMPLING; ENZYME INHIBITION; HEART HEMODYNAMICS; HEART LEFT ATRIUM PRESSURE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; LUNG ARTERY PRESSURE; PIG; REST; VASOMOTOR REFLEX;

ANIMALS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; FEMALE; HYPERTENSION, PULMONARY; MALE; MYOCARDIAL INFARCTION; NITRIC OXIDE; PHYSICAL CONDITIONING, ANIMAL; PROSTAGLANDINS; PULMONARY CIRCULATION; SWINE; VASOCONSTRICTION; VASOMOTOR SYSTEM;

EID: 34249850239     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.127118     Document Type: Article

References (66)

1. Ahlborg G & Lundberg JM (1997). Nitric oxide-endothelin-1 interaction in humans. J Appl Physiol 82, 1593-1600.
2. 2 and nitric oxide involvement in the regulation of systemic and pulmonary basal vascular tone in the pig. Prostaglandins Leukot Essent Fatty Acids 54, 273-278.
3. Alonso D & Radomski MW (2003). The nitric oxide-endothelin-1 connection. Heart Fail Rev 8, 107-115.
4. Armstrong RB, Delp MD, Goljan EF & Laughlin MH (1987). Distribution of blood flow in muscles of miniature swine during exercise. J Appl Physiol 62, 1285-1298.
5. Baber SR, Deng W, Rodriguez J, Master RG, Bivalacqua TJ, Hyman AL & Kadowitz PJ (2005). Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse. Am J Physiol Heart Circ Physiol 289, H1476-H1487.
6. Baggia S, Perkins K & Greenberg B (1997). Endothelium-dependent relaxation is not uniformly impaired in chronic heart failure. J Cardiovasc Pharmacol 29, 389-396.
7. Bake B, Wood L, Murphy B, Macklem PT & Milic-Emili J (1974). Effect of inspiratory flow rate on regional distribution of inspired gas. J Appl Physiol 37, 8-17.
8. Ben Driss A, Devaux C, Henrion D, Duriez M, Thuillez C, Levy BI & Michel JB (2000). Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure. Circulation 101, 2764-2770.
9. Budhiraja R, Tuder RM & Hassoun PM (2004). Endothelial dysfunction in pulmonary hypertension. Circulation 109, 159-165.
10. Butler J, Chomsky DB & Wilson JR (1999). Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 34, 1802-1806.
11. Cooper CJ, Jevnikar FW, Walsh T, Dickinson J, Mouhaffel A & Selwyn AP (1998). The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 82, 609-614.
12. Dawson CA (1984). Role of pulmonary vasomotion in physiology of the lung. Physiol Rev 64, 544-616.
13. Docherty CC & MacLean MR (1998). EndothelinB receptors in rabbit pulmonary resistance arteries: Effect of left ventricular dysfunction. J Pharmacol Exp Ther 284, 895-903.
14. Duncker DJ, Haitsma DB, Liem DA, Verdouw PD & Merkus D (2005). Exercise unmasks autonomic dysfunction in swine with a recent myocardial infarction. Cardiovasc Res 65, 889-896.
15. 2-consumption in exercising swine. Cardiovasc Res 47, 738-748.
16. Duncker DJ, Stubenitsky R & Verdouw PD (1998). Role of adenosine in the regulation of coronary blood flow in swine at rest and during treadmill exercise. Am J Physiol Heart Circ Physiol 275, H1663-H1672.
17. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, Bonan R & Crepeau J (1998a). Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 135, 614-620.
18. Dupuis J, Rouleau JL & Cernacek P (1998b). Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 98, 1684-1687.
19. Ermert L, Ermert M, Goppelt-Struebe M, Walmrath D, Grimminger F, Steudel W, Ghofrani HA, Homberger C, Duncker H & Seeger W (1998). Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol 18, 479-488.
20. Falcone JC & Meininger GA (1999). Endothelin mediates a component of the enhanced myogenic responsiveness of arterioles from hypertensive rats. Microcirculation 6, 305-313.
21. Franciosa JA, Baker BJ & Seth L (1985). Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J 110, 807-813.
22. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP & Stewart DJ (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328, 1732-1739.
23. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB & Bahou WF (1994). Termination of endothelin signaling: Role of nitric oxide. J Cell Physiol 158, 485-494.
24. Gomez-Alamillo C, Juncos LA, Cases A, Haas JA & Romero JC (2003). Interactions between vasoconstrictors and vasodilators in regulating hemodynamics of distinct vascular beds. Hypertension 42, 831-836.
25. Guarracino F, Cariello C, Danella A, Doroni L, Lapolla F, Vullo C, Pasquini C & Stefani M (2005). Right ventricular failure: Physiology and assessment. Minerva Anestesiol 71, 307-312.
26. Haitsma DB, Bac D, Raja N, Boomsma F, Verdouw PD & Duncker DJ (2001). Minimal impairment of myocardial blood flow responses to exercise in the remodeled left ventricle early after myocardial infarction, despite significant hemodynamic and neurohumoral alterations. Cardiovasc Res 52, 417-428.
27. Haitsma DB, Merkus D, Vermeulen J, Verdouw PD & Duncker DJ (2002). Nitric oxide production is maintained in exercising swine with chronic left ventricular dysfunction. Am J Physiol Heart Circ Physiol 282, H2198-H2209.
28. Hampl V & Herget J (2000). Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 80, 1337-1372.
29. Hastings AB, White FC, Sanders TM & Bloor CM (1982). Comparative physiological responses to exercise stress. J Appl Physiol 52, 1077-1083.
30. Houweling B, Merkus D, Dekker MM & Duncker DJ (2005). Nitric oxide blunts the endothelin-mediated pulmonary vasoconstriction in exercising swine. J Physiol 568, 629-638.
31. Houweling B, Merkus D, Sorop O, Boomsma F & Duncker DJ (2006). Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction. J Physiol 574, 615-626.
32. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF & Rabinovitch M (2004). Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43, 13S-24S.
33. Kelly LK, Wedgwood S, Steinhorn RH & Black SM (2004). Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol Lung Cell Mol Physiol 286, L984-L991.
34. Krum H, Goldsmith R, Wilshire-Clement M, Miller M & Packer M (1995). Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 75, 1282-1283.
35. Langleben D, Barst RJ, Badesch D, Groves BM, Tapson VF, Murali S, Bourge RC, Ettinger N, Shalit E, Clayton LM, Jobsis MM, Blackburn SD, Crow JW, Stewart DJ & Long W (1999). Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 99, 3266-3271.
36. Langleben D, Dupuis J, Hirsch A, Giovinazzo M, Langleben I, Khoury J, Ruel N & Caron A (2005). Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. Chest 128, 622S.
37. Laughlin MH, Klabunde RE, Delp MD & Armstrong RB (1989). Effects of dipyridamole on muscle blood flow in exercising miniature swine. Am J Physiol Heart Circ Physiol 257, H1507-H1515.
38. Lavallee M, Takamura M, Parent R & Thorin E (2001). Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 6, 265-276.
39. Mabee SW, Metra M, Reed DE, Dei Cas L & Cody RJ (1994). Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure. J Card Fail 1, 27-33.
40. Marcelin-Jimenez G & Escalante B (2001). Functional and cellular interactions between nitric oxide and prostacyclin. Comp Biochem Physiol C Toxicol Pharmacol 129, 349-359.
41. McLaughlin VV & McGoon MD (2006). Pulmonary arterial hypertension. Circulation 114, 1417-1431.
42. Merkus D, Haitsma DB, Sorop O, Boomsma F, de Beer VJ, Lamers JM, Verdouw PD & Duncker DJ (2006). Coronary vasoconstrictor influence of angiotensin II is reduced in remodeled myocardium after myocardial infarction. Am J Physiol Heart Circ Physiol 291, H2082-H2089.
43. Merkus D, Houweling B, Mirza A, Boomsma F, van den Meiracker AH & Duncker DJ (2003). Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation. Cardiovasc Res 59, 745-754.
44. Merkus D, Houweling B, van den Meiracker AH, Boomsma F & Duncker DJ (2005). Contribution of endothelin to coronary vasomotor tone is abolished after myocardial infarction. Am J Physiol Heart Circ Physiol 288, H871-H880.
45. Merkus D, Houweling B, Zarbanoui A & Duncker DJ (2004). Interaction between prostanoids and nitric oxide in regulation of systemic, pulmonary, and coronary vascular tone in exercising swine. Am J Physiol Heart Circ Physiol 286, H1114-H1123.
46. Metra M, Nardi M, Giubbini R & Dei Cas L (1994). Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24, 1678-1687.
47. Moraes DL, Colucci WS & Givertz MM (2000). Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management. Circulation 102, 1718-1723.
48. Newman JH, Butka BJ & Brigham KL (1986). Thromboxane A2 and prostacyclin do not modulate pulmonary hemodynamics during exercise in sheep. J Appl Physiol 61, 1706-1711.
49. Nodari S, Metra M & Dei Cas L (2003). Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 5, 621-627.
50. Ontkean M, Gay R & Greenberg B (1991). Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69, 1088-1096.
51. Osanai T, Fujita N, Fujiwara N, Nakano T, Takahashi K, Guan W & Okumura K (2000). Cross talk of shear-induced production of prostacyclin and nitric oxide in endothelial cells. Am J Physiol Heart Circ Physiol 278, H233-H238.
52. Petersen HH, Choy J, Stauffer B, Moien-Afshari F, Aalkjaer C, Leinwand L, McManus BM & Laher I (2002). Coronary artery myogenic response in a genetic model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 283, H2244-H2249.
53. Prins B, Hu R, Nazario B, Pedram A, Frank H, Weber M & Levin E (1994). Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 269, 11938-11944.
54. Puybasset L, Bea ML, Ghaleh B, Giudicelli JF & Berdeaux A (1996). Coronary and systemic hemodynamic effects of sustained inhibition of nitric oxide synthesis in conscious dogs. Evidence for cross talk between nitric oxide and cyclooxygenase in coronary vessels. Circ Res 79, 343-357.
55. Reeves JT & Taylor AE (1996). Pulmonary hemodynamics and fluid exchange in the lungs during exercise. Handbook of Physiology, section 12, Exercise: Regulation and Integration of Multiple Systems, ed. Rowell LB & Shepherd JT, pp. 585-613. Oxford University Press, New York.
56. Richard V, Hogie M, Clozel M, Loffler B-M & Thuillez C (1995). In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 91, 771-775.
57. Said SI (2006). Mediators and modulators of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 291, L547-L558.
58. Sartori C, Lepori M & Scherrer U (2005). Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 106, 209-220.
59. Sauvageau S, Thorin E, Caron A & Dupuis J (2006). Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 231, 840-846.
60. Schiffrin EL & Touyz RM (1998). Vascular biology of endothelin. J Cardiovasc Pharmacol 32, S2-S13.
61. Spieker LE, Noll G & Luscher TF (2001). Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am J Cardiovasc Drugs 1, 293-303.
62. Staniloae C, Dupuis J, White M, Gosselin G, Dyrda I, Bois M, Crepeau J, Bonan R, Caron A & Lavoie J (2004). Reduced pulmonary clearance of endothelin in congestive heart failure: A marker of secondary pulmonary hypertension. J Card Fail 10, 427-432.
63. 2 delivery and utilization in swine during treadmill exercise. Cardiovasc Res 39, 459-474.
64. von Lueder TG, Kjekshus H, Edvardsen TEOI, Urheim S, Vinge LE, Ahmed MS, Smiseth OA & Attramadal H (2004). Mechanisms of elevated plasma endothelin-1 in CHF: Congestion increases pulmonary synthesis and secretion of endothelin-1. Cardiovasc Res 63, 41-50.
65. Wiley KE & Davenport AP (2001). Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system. Br J Pharmacol 132, 213-220.
66. Wort SJ, Woods M, Warner TD, Evans TW & Mitchell JA (2002). Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: Implications for pulmonary hypertension. Mol Pharmacol 62, 1147-1153.